Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clene Inc. CLNN

Healthcare Biotechnology
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8... see more

Recent & Breaking News (NDAQ:CLNN)

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

GlobeNewswire March 9, 2021

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

GlobeNewswire March 3, 2021

Clene Nanomedicine Awarded Michael J. Fox Foundation Grant to Accelerate the Development of CNM-Au8 as a Treatment for Parkinson's Disease

GlobeNewswire March 1, 2021

Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

GlobeNewswire February 25, 2021

Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

GlobeNewswire February 19, 2021

Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19

GlobeNewswire February 16, 2021

Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis

GlobeNewswire January 19, 2021

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update

GlobeNewswire December 30, 2020